Lidocaine SR is under clinical development by Sustained Therapeutics and currently in Phase II for Post-Operative Pain. According to GlobalData, Phase II drugs for Post-Operative Pain have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lidocaine SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lidocaine SR overview
ST-01 is under investigation for the treatment of post-operative pain, chronic scrotal pain and chronic pelvic pain. The drug candidate is a sustained-release lidocaine polymer formulation administered perineurally.
Sustained Therapeutics overview
Sustained Therapeutics (Sustained) provides bio technology, healthcare, pharmaceutical, life sciences and other services. Sustained is headquartered in Vancouver, British Columbia, Canada.
For a complete picture of Lidocaine SR’s drug-specific PTSR and LoA scores, buy the report here.